Tue.Dec 12, 2023

article thumbnail

Tome Biosciences debuts with $213M and a new way to edit the genome

Bio Pharma Dive

Based on the work of MIT scientists, the well-funded startup is developing ways to insert large sizes of genetic material anywhere in the genome without damaging or breaking DNA.

Genome 323
article thumbnail

December 12, 2023: A Year of New Insights From the NIH Pragmatic Trials Collaboratory

Rethinking Clinical Trials

Investigators from the NIH Pragmatic Trials Collaboratory in 2023 shared study results, generated new knowledge, and developed innovative methods in the design, conduct, and analysis of pragmatic clinical trials. Their work included insights from the Coordinating Center and Core Working Groups , analyses from the Distributed Research Network , and study designs and results from the NIH Collaboratory Trials.

Trials 141
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FTC, in unusual move, leads Sanofi to terminate a drug research deal

Bio Pharma Dive

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.

Licensing 291
article thumbnail

Bicara raises $165m to advance cancer therapy  

Pharmaceutical Technology

The funding will advance Bicara’s lead candidate BCA101, with the EGFR/TGF-β inhibitor currently being evaluated in Phase II clinical trials.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B

Bio Pharma Dive

The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses.

article thumbnail

Sanofi bows to FTC demands and ends Maze licensing deal

Pharmaceutical Technology

The license of Maze’s GYS1 program, including MZE-001, was the subject of FTC opposition, leading to Sanofi terminating the agreement

Licensing 130

More Trending

article thumbnail

Europe names hundreds of critical medicines in quest to counter drug shortages

Fierce Pharma

Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S. | Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages. Inclusion in the list doesn’t mean a particular drug is likely to experience a shortage anytime soon, the EMA said.

Medicine 138
article thumbnail

Imeik Technology Development sees highest patent filings and grants during July in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Imeik Technology Development here.

article thumbnail

Grand Rounds December 8, 2023: A Pragmatic Randomized Trial of the Jumpstart Intervention to Promote Communication about Goals of Care for Hospitalized Patients with Serious Illness (Ruth Engelberg, PhD; Erin Kross, MD; Robert Lee, MD, MS)

Rethinking Clinical Trials

         Speakers Ruth Engelberg, PhD Research Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine University of Washington Erin Kross, MD Associate Professor of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine University of Washington Robert Lee, MD, MS Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine University of Washington Slides Keywords Jumpstart, Advanced Planning, Goals of Care Key Points Researche

Trials 130
article thumbnail

10 achondroplasia facts to note

Antidote

Achondroplasia, a term meaning “without cartilage formation,” is a genetic disorder leading to disproportionate short stature. Sometimes called achondroplastic dwarfism or ACH , this condition has few treatment options and no known cure. However, individuals diagnosed with this condition can typically lead fulfilling, healthy lives with proper management.

Genetics 121
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Pfizer reveals reorganization, executive departure as it gets ready to close $43B Seagen buyout

Fierce Pharma

To complete its acquisition of Seagen, what did Pfizer need to do to satisfy antitrust concerns of the Federal Trade Commission? | By agreeing to donate royalties on its U.S. sales of bladder cancer drug Bavencio, Pfizer has received the go-ahead to finalize its $43 billion buyout of Seagen, the company said on Tuesday. Pfizer expects to close the merger on Thursday.

Sales 115
article thumbnail

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. These components make plasma an invaluable resource for treating various medical conditions, especially those that are rare and chronic.

Medicine 111
article thumbnail

HIV pathology data now reaching investigators within hours thanks to Proscia software

Outsourcing Pharma

The AIDS and Cancer Specimen (ACSR), a biorepository of specimens collected from persons living with HIV (PLWH) has today (December 12) announced it is using software from Proscia that can provide near real-time access to pathology data to investigators around the world.

article thumbnail

Navigating Neuroscience Trials: Biomarkers, Imaging and CRO Strategies

XTalks

The world of neuroscience trials is rapidly evolving, presenting new challenges and opportunities for researchers and clinicians. The worldwide market for neurology clinical trials stood at a valuation of $5.24 billion in 2022. It’s projected to grow at a compound annual growth rate (CAGR) of 5.6 percent between 2023 and 2030. This growth is primarily being driven by a rise in neurological diseases like stroke, dementia and peripheral neuropathy, coupled with increased R&D funding for neurol

Trials 111
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

UCL picks ViroCell as partner for childhood cancer treatment

BioPharma Reporter

ViroCell Biologics, a London-based viral vector CDMO for cell and gene therapy clinical trials, has partnered with University College London (UCL) to advance its pediatric cancer treatment.

article thumbnail

White Claw Enters Non-Alcoholic Beverage Market

XTalks

White Claw is entering the non-alcoholic beverage space with its latest innovation, the White Claw 0% Alcohol seltzers. Offering a new twist on traditional flavors, these drinks come in black cherry cranberry, mango passionfruit, peach orange blossom and lime yuzu. Designed to mirror the taste of the original White Claw Hard Seltzers, these 12-ounce beverages contain only 15 calories per can and are infused with electrolytes for added hydration benefits.

Marketing 104
article thumbnail

Guangzhou Kingmed Diagnostics Group sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Guangzhou Kingmed Diagnostics Group here.

130
130
article thumbnail

PharmaKure partners with Malaysian university in a bid to predict neurological diseases

Outsourcing Pharma

Clinical-stage pharma company, PharmaKure which develops precision medicine for Alzheimerâs Disease and other neurological diseases has announced a collaboration agreement with one of the largest comprehensive universities in Malaysia.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

China Traditional Chinese Medicine sees highest patent filings and grants during July in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for China Traditional Chinese Medicine here.

Medicine 100
article thumbnail

Ferring trims US workforce by 134 with layoffs in New Jersey, Minnesota

Fierce Pharma

As waves of layoffs continue to hit the biopharma industry, Ferring Pharmaceuticals is trimming its headcount by 134 across its two U.S. locations. | The drugmaker will lay off 79 at its New Jersey headquarters and 55 at its microbiome subsidiary Rebiotix in Minnesota as a result of a "revised business strategy.

98
article thumbnail

Zhejiang Jiuzhou Pharmaceutical sees highest patent filings and grants during July in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Zhejiang Jiuzhou Pharmaceutical here.

100
100
article thumbnail

Babies born early have an increased risk of developmental disorders

Pharma Times

Around 240 million children worldwide are living with these types of disorders - News - PharmaTimes

125
125
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

In Musk Era, Pharma Companies Move Ads Away From X

BioSpace

Even before its billionaire owner made recent headlines by endorsing an antisemitic post and hurling an expletive at advertisers, biopharma companies had begun to find different uses for their advertisement budgets.

article thumbnail

Idorsia Pharmaceutical sees highest patent filings and grants during September in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Idorsia Pharmaceutical here.

100
100
article thumbnail

Genentech elevates interim CEO Ashley Magargee to full-time leadership position

Fierce Pharma

Genentech’s brief leadership interregnum is coming to an end as the company’s interim chief executive, Ashley Magargee, prepares to take a permanent place on the throne. | Genentech veteran Ashley Magargee, who was tapped to temporarily steer the Roche subsidiary in November, will don the mantle of full-time CEO on Jan. 1, 2024. The executive move comes amid a period of C-suite fluidity for Roche and its large pharma group.

96
article thumbnail

MAPS PBC Submits First NDA to FDA for Psychedelic-Assisted Therapy

BioSpace

If approved by the FDA, the MDMA-assisted treatment for individuals with post-traumatic stress disorder would be the first U.S. psychedelic-assisted therapy.

102
102
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Novartis’ Fabhalta Gets FDA Approval for Rare Complement Blood Disorder

XTalks

After receiving US Food and Drug Administration (FDA) approval for Fabhalta (iptacopan) last week for the treatment of the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH), Novartis presented trial data yesterday showing the drug’s promise in another indication. Fabhalta, the highly anticipated factor B inhibitor touted to be a blockbuster by industry analysts, is the first FDA-approved oral monotherapy for PNH.

article thumbnail

Genscript Biotech sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for Genscript Biotech here.

100
100
article thumbnail

FDA Creates Adcomm for Genetic Metabolic Diseases and Potential Treatments

BioSpace

Ahead of an expected surge in regulatory filings, the FDA is establishing the Genetic Metabolic Diseases Advisory Committee to provide advice on treatments for these complex and challenging conditions.

article thumbnail

WuXi AppTec sees highest patent filings and grants during August in Q3 2023

Pharmaceutical Technology

Access and buy GlobalData’s databook on the latest filings and grants activity for WuXi AppTec here.

100
100
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.